Focus on
Learning Objectives
After watching this webinar, participants will be able to understand:
- The role of advanced CMR during the cancer process;
- Which tools may help us to prevent cancer therapy related cardiovascular toxicity;
- How to perform an early diagnosis of subclinical left ventricular dysfunction and how to manage this information for clinical decision making;
- Who needs a CMR throughout the cancer process;
- When a CMR improves cardiotoxicity diagnosis.
Professor Daniel Lenihan, FESC
Professor Valentina Püntmann
Professor Jeroen Bax, FESC
Our mission: To reduce the burden of cardiovascular disease.